Total Endovascular Aortic Arch Re-construction Study(TEARS)

Overview

The purpose of this study is to investigate the short to mid term efficacy and safety of a newly-developed branched stent graft in patients who had complex aortic lesions, such as ascending aortic/arch aneurysm, pseudo-aneurysm, Stanford Type A dissection, retrograde Stanford Type B dissection, dissection with primary tear located in the aortic arch, et al.

Full Title of Study: “Total Endovascular Aortic Arch Re-construction Study(TEARS)——China’s Registry”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: December 2018

Detailed Description

Aneurysms and dissection involving the ascending aorta and aortic arch have historically been treated with open surgical techniques, requiring cardiopulmonary bypass and deep hypothermic circulatory arrest (DHCA). Despite increasing experience and refinement of these procedures, there remains a substantial rate of morality and morbidity. Total endovascular aortic arch and ascending aorta repair is one of the ultimate solutions of these diseases. However, this approach requires extensive technique and new device development. The goal of total endoluminal stent grafting is to re-construct the ascending aorta and aortic arch to cover the primary entry tear of the dissection and to remodel the aorta.Recently, branch and fenestrated stent-grafts has been developed to treat complex ascending and aortic arch disease, which was previously considered to be contraindicated for endovascular repair. This study aims to investigate the short to mid term efficacy and safety of a newly-developed branched stent graft in patients who had complex aortic lesions, such as ascending aortic/arch aneurysm, pseudo-aneurysm, Stanford Type A dissection, retrograde Stanford Type B dissection, dissection with primary tear located in the aortic arch, et al. Primary outcome measure is all-cause mortality. Secondary outcome variables include conversion to stent and/or surgery, induced thrombosis of the false lumen, cardiovascular morbidity, aortic expansion (>5 mm/y of maximum diameter including true and false lumina), quality of life, and length of intensive care unit and hospital stay. The study designs to enroll 50 patients to be monitored for 24 months.

Interventions

  • Device: Ankura Branched/Fenestrated Stent Graft
    • Ankura Branched/Fenestrated Stent Graft(Lifetech Scientific Co.,LTD.,Shenzhen, China)

Arms, Groups and Cohorts

  • Experimental: Endovascular
    • Total endovascular arch reconstruction

Clinical Trial Outcome Measures

Primary Measures

  • cumulative MACE (including death, rupture, paraplegia, aneurysm formation)
    • Time Frame: 12 months

Secondary Measures

  • Endoleak
    • Time Frame: 12 months
    • Endoleak of all types
  • Stent-graft migration/kinking
    • Time Frame: 12 months
    • Stent-graft migration, stenosis, kinking and other conditions requiring re-intervention
  • cumulative cerebrovascular events
    • Time Frame: 12 months
    • cumulative cerebrovascular events

Participating in This Clinical Trial

Inclusion Criteria

1. Ascending aortic/arch aneurysm 2. Ascending aortic/arch pseudo-aneurysm 3. Stanford Type A dissection 4. Retrograde Stanford Type B dissection 5. Unclassified dissection with primary tear located in the aortic arch 6. Able to tolerate endotracheal intubation and general anesthesia 7. Subject's anatomy must meet the anatomical criteria to receive that implanted device 8. The subject or legal guardian understands the nature of the study and agrees to its provisions on a written informed consent form 9. Availability for the appropriate follow-up visits during the follow-up period 10. Capability to follow all study requirements Exclusion Criteria:

1. ASA classification = V 2. Severe renal insufficiency defined as SVS risk renal status = 3 3. Severe respiratory insufficiency defined as SVS risk pulmonary status = 3 4. Presence of connective tissue disease 5. Active infection or active vasculitides 6. Pregnant woman or positive pregnancy test 7. Myocardial infarction or cerebrovascular accident within 6 weeks prior to study enrollment 8. Subject has had a cerebral vascular accident (CVA) within 2 months. 9. History of drug abuse 10. Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion. 11. Subject has a known allergy or intolerance to the device components. 12. Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment. 13. Subject has a co-morbidity causing expected survival to be less than 1 year. 14. Enrolment in another clinical study 15. Unwillingness to cooperate with study procedures or follow-up visits

Gender Eligibility: All

Minimum Age: 12 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Xijing Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jian Yang, MD,PhD, Principal Investigator, Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University
    • Dinghua Yi, M.D., PhD., Study Chair, Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University
  • Overall Contact(s)
    • Jian Yang, MD,PhD, 86-13892828016, yangjian1212@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.